Program
The Policy Summit brings together policymakers, industry leaders, and science stakeholders to discuss emerging issues in the cell and gene therapy field and explore innovative solutions. You’ll connect with experts in the field in an environment designed for meaningful discussion and collaboration. This dynamic 1.5-day event includes fireside chats with leaders in the field, in-person networking opportunities, expert-led presentations, and audience Q&A.
Check back on this page and subscribe to ASGCT’s The Advocate newsletter for agenda updates as speakers are confirmed. All sessions subject to change.
Tell us what you're excited for at the Policy Summit by sharing your favorite speakers, topics, and sessions on social media using #ASGCTadvocacy!
Register to join us in Washington, D.C.
Thursday September 25, 2025
All times are in ET
9 – 9:05 a.m. ET - Policy Summit Opening Remarks
9:05 – 10:20 a.m. ET - European Value Assessment and Payment Systems for CGTs
-
Francis Pang, Orchard Therapeutics
Industry Perspective on European Valuation and Payment Systems
-
Damjan Osredkar, MD, PhD, University Medical Centre Ljubljana
Patient Advocate Perspective on European Valuation and Payment Systems
10:20 – 10:50 a.m. ET - Networking Break
10:50 – 11:50 a.m. ET - Development Pathways for Rare Disease Therapies
-
Kira Gillett, Foundation for the National Institutes of Health
Bespoke Gene Therapy Consortium: Overview and Updates
-
Helen Heslop, MD, Baylor College of Medicine
Exploring Alternative Development Pathways: The Access 4 Kids Approach
-
Moderator: Terence Flotte, MD, UMass Chan Medical School
11:50 a.m. – 12:35 p.m. ET - Session to be Announced
12:35 – 1:35 p.m. ET - Lunch
1:35 – 2:30 p.m. ET - Addressing CGT Bottlenecks: Focus on Clinical Care
-
Jeff Wagner, PharmD, Texas Children’s Hospital
Onboarding CGTs for Commercial Use: A Hospital System Perspective
-
Geoffrey Lomax, DrPH, California Institute for Regenerative Medicine
Bringing Care Closer to Patients: Inpatient, Outpatient, and Community Care Considerations
-
Drew Campbell, MD, Children’s National Hospital
Coordinated Care for Patients Receiving CGTs: Learnings from SCD
-
Moderator: Susan Matesanz, MD, Children’s Hospital of Philadelphia
2:30 – 3:00 p.m. ET - Focus on Capitol Hill: Bipartisan Congressional Staff Chat
3 – 3:30 p.m. - Networking Break
3:30 – 4:15 p.m. ET - Session to be Announced
4:15 – 5 p.m. ET - Session to be Announced
5 – 6:30 p.m. ET - Networking Reception
Friday September 26, 2025
9 – 10:15 a.m. ET - Artificial Intelligence for Genetic Medicine Development
- Amy Pooler, PhD, Life Edit Therapeutics
Utilizing AI in Drug Discovery and Trial Design: Focus on Gene Editing
-
Tyson Bertmaring, Dyno Therapeutics
Utilizing AI in Drug Discovery and Trial Design: Focus on AAV
-
Moderator: Barrett Tenbarge, JD, Faegre Drinker
10:15 – 10:45 a.m. ET - Networking Break
10:45 a.m. – 12 p.m. ET - Regulatory Harmonization to Address CMC Challenges
-
Kathleen Francissen, PhD, Genentech
The ICH Cell & Gene Therapy Discussion Group: Overview and Updates
-
Sadik Kassim, PhD, Danaher Genomic Medicines
Harmonization of CMC Standards for ‘N of 1’ and ‘N of Few’ Patients
-
Brian Shy, MD, PhD, University of California San Francisco
Harmonizing Requirements for Starting Biological Materials
-
Moderator: Jessica Tate, PhD, Centre for Commercialization of Regenerative Medicine
Register Now
ASGCT is a 501(c)3 tax-exempt organization and does not participate in any political activity, either directly or indirectly, including support for or against campaigns for public office. The participation of speaker(s) who are elected officials, members of their staff, members of the governing administration, and/or former members of these offices (“government officials”), does not indicate support for or against any political party, political party agenda, or candidate for public office. Any government official who is also a speaker at an ASGCT-sponsored event is permitted to discuss topics related exclusively to the mission of the Society and is expressly prohibited from discussing any campaign for public office or other political activity.